Story perspectives

Abivax Shares Jump 40% on Strong Remission Data

7/1/2026

Summary

Abivax Shares Surge

Abivax shares rose 39.9% to €116.5 on June 30, 2026 after obefazimod data were released.
Cancer cases matched background ulcerative colitis rates, easing safety concerns.
The 50 mg dose yielded 37.2% clinical remission and 34.5% endoscopic remission after ten months.
Safety monitoring of 1,704 exposures recorded four non-melanoma skin cancers and two other malignancies in patients with risk factors.
Analysts Stifel, Oddo BHF and Piper Sandler kept buy or outperform ratings, citing the safety profile.

Summary

Abivax Files NDA

Abivax plans a U.S. NDA filing for obefazimod in ulcerative colitis in Q4 2026, having spent €49.5 million on R&D in Q1, 94.5 % on drug.
After repurchasing royalty certificates for $90 million with cash and 403,347 ADSs, CFO Didier Blondel said strengthening the balance sheet is a core priority.
Phase 2b topline results for obefazimod in Crohn’s disease are due mid-2027, while Merck’s ulcerative colitis candidate met primary and key secondary goals, raising competition.

History

Historical Context

In 1998 the FDA approved Johnson & Johnson’s infliximab, the first TNF-blocking biologic, and in 2006 extended its label to ulcerative colitis, creating the anti-TNF market. Its $1.2 billion U.S. sales by 2010 spurred rivals such as Abbott’s adalimumab (approved 2002) and today’s Merck 2024 push and Abivax’s €49.5 million R&D spend.

1 of 3

Abivax Shares Surge

Abivax shares rose 39.9% to €116.5 on June 30, 2026 after obefazimod data were released.
Cancer cases matched background ulcerative colitis rates, easing safety concerns.
The 50 mg dose yielded 37.2% clinical remission and 34.5% endoscopic remission after ten months.
Safety monitoring of 1,704 exposures recorded four non-melanoma skin cancers and two other malignancies in patients with risk factors.
Analysts Stifel, Oddo BHF and Piper Sandler kept buy or outperform ratings, citing the safety profile.

1 / 3